These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 23842135)
1. Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study. Prach LM; Pascopella L; Barry PM; Flood J; Porco TC; Hopewell PC; Metcalfe JZ AIDS; 2013 Oct; 27(16):2615-22. PubMed ID: 23842135 [TBL] [Abstract][Full Text] [Related]
2. Rifampin-resistant Tuberculosis in the United States, 1998-2014. Sharling L; Marks SM; Goodman M; Chorba T; Mase S Clin Infect Dis; 2020 Apr; 70(8):1596-1605. PubMed ID: 31233131 [TBL] [Abstract][Full Text] [Related]
3. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307 [TBL] [Abstract][Full Text] [Related]
4. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122 [TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. Park S; Jo KW; Lee SD; Kim WS; Shim TS Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study. Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283 [TBL] [Abstract][Full Text] [Related]
7. Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions. Sanchez-Padilla E; Ardizzoni E; Sauvageot D; Ahoua L; Martin A; Varaine F; Adatu-Engwau F; Akeche G; Salaniponi F; Bonnet M Int J Tuberc Lung Dis; 2013 Aug; 17(8):1036-42. PubMed ID: 23827027 [TBL] [Abstract][Full Text] [Related]
8. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis. Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736 [TBL] [Abstract][Full Text] [Related]
9. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Mukinda FK; Theron D; van der Spuy GD; Jacobson KR; Roscher M; Streicher EM; Musekiwa A; Coetzee GJ; Victor TC; Marais BJ; Nachega JB; Warren RM; Schaaf HS Int J Tuberc Lung Dis; 2012 Feb; 16(2):196-202. PubMed ID: 22236920 [TBL] [Abstract][Full Text] [Related]
10. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. Fox L; Kramer MR; Haim I; Priess R; Metvachuk A; Shitrit D Eur J Clin Microbiol Infect Dis; 2011 Jul; 30(7):863-7. PubMed ID: 21431989 [TBL] [Abstract][Full Text] [Related]
11. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil. Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771 [TBL] [Abstract][Full Text] [Related]
12. Drug-resistant TB prevalence study in 5 health institutions in Haiti. Hoffmann J; Chedid C; Ocheretina O; Masetti C; Joseph P; Mabou MM; Mathon JE; Francois EM; Gebelin J; Babin FX; Raskine L; Pape JW PLoS One; 2021; 16(3):e0248707. PubMed ID: 33735224 [TBL] [Abstract][Full Text] [Related]
13. Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study. He XC; Zhang XX; Zhao JN; Liu Y; Yu CB; Yang GR; Li HC Medicine (Baltimore); 2016 Apr; 95(15):e3336. PubMed ID: 27082586 [TBL] [Abstract][Full Text] [Related]
14. High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. Velayati AA; Farnia P; Mozafari M; Sheikholeslami MF; Karahrudi MA; Tabarsi P; Hoffner S Am J Trop Med Hyg; 2014 Jan; 90(1):99-105. PubMed ID: 24189362 [TBL] [Abstract][Full Text] [Related]
15. Rifampin-resistant, isoniazid-susceptible TB in HIV patients. Pugliese G Infect Control Hosp Epidemiol; 1995 Nov; 16(11):622. PubMed ID: 8601679 [No Abstract] [Full Text] [Related]
16. Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. Baghaei P; Tabarsi P; Moniri A; Marjani M; Farnia P; Jabbehdari S; Velayati AA J Glob Antimicrob Resist; 2017 Dec; 11():116-119. PubMed ID: 28739225 [TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance among persons with tuberculosis in California, 1994-2003. Granich RM; Oh P; Lewis B; Porco TC; Flood J JAMA; 2005 Jun; 293(22):2732-9. PubMed ID: 15941802 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995. Liu Z; Shilkret KL; Finelli L Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705 [TBL] [Abstract][Full Text] [Related]
19. Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy. Sungkanuparph S; Eampokalap B; Chottanapund S; Bed ST; Manosuthi W J Med Assoc Thai; 2007 May; 90(5):884-8. PubMed ID: 17596041 [TBL] [Abstract][Full Text] [Related]
20. Nationwide survey of drug-resistant tuberculosis in the United States. Bloch AB; Cauthen GM; Onorato IM; Dansbury KG; Kelly GD; Driver CR; Snider DE JAMA; 1994 Mar; 271(9):665-71. PubMed ID: 8080502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]